GlassScriptPhysician profile
Bridgett L Buckman
NPI 1104907765
$982.81
in general payments reported to CMS, 2019-2025
20 companies · $31.44 in 2025
The $31.44 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $540 · 2024: $411 · 2025: $31.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.37 | 2023-2024 | |
| Abbott Laboratories | $95.95 | 2024-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.89 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $69.63 | 2023 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $67.21 | 2024 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $63.71 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $49.78 | 2023-2024 | Camzyos |
| Lundbeck LLC | $41.77 | 2023 | Rexulti |
| Lilly USA, LLC | $39.27 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Sumitomo Pharma America, INC. | $35.05 | 2023 | Gemtesa |
| Pfizer INC. | $31.53 | 2023 | |
| Novartis Pharmaceuticals Corporation | $31.44 | 2023 | |
| Amgen INC. | $30.40 | 2023 | Prolia, Evenity, Repatha |
| Exact Sciences Corporation | $28.87 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $27.15 | 2023-2024 | Breztri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.83 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $21.47 | 2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.61 | 2024 | Jardiance |
| Dexcom, INC. | $15.37 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $13.51 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgett Buckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.